Global Health Press
Undetectable viral load at time of immunisation enhances yellow fever vaccine protection for people with HIV

Undetectable viral load at time of immunisation enhances yellow fever vaccine protection for people with HIV

shutterstock_214353211Viral suppression at the time of immunisation is the most important determinant of long-term response to yellow fever vaccination among people with HIV, Swiss investigators report in Clinical Infectious Diseases. Every person with an undetectable viral load at the time of first yellow fever vaccination continued to have a protective response ten years after vaccination, they found.

“Persons infected with HIV demonstrated good short-term immune response to YFV [yellow fever vaccination], which decreased to 75% ten years p.v. [post vaccination,” comment the authors. “The long-term immune response of patients with HIV RNA suppressed at vaccination remained unimpaired for up to ten years.”

The investigators believe their findings have implications for vaccination strategies, writing: “HIV-infected patients mount a long-standing protective immune response to YFV up to at least ten years if they are vaccinated while remaining on successful cART [combination antiretroviral therapy]…until further data are available a single booster after ten years seems to be adequate to restimulate the vaccine response in the event of new travel to a YF [yellow fever] endemic area.”

Yellow fever is a mosquito-borne severe viral haemorrhagic disease. There is no antiviral treatment. However, there is a highly effective vaccine. The World Health Organization issued guidance in 2013 recommending that individuals should receive yellow fever vaccination boosters every ten years to obtain life-long protection against the disease.

Many HIV-positive individuals live in or travel to areas where yellow fever is endemic. The long-term response to yellow fever vaccination in patients with HIV is poorly understood. Investigators from the Swiss HIV Cohort Study therefore identified 247 patients with a documented first yellow fever vaccination after their diagnosis with HIV. Stored blood samples were examined to see if patients had an immune response at one, five and ten years post-vaccination. A yellow fever plaque reduction neutralisation titre (PRNT) of 1: >10 was regarded as reactive and protective. Predictors of vaccine response were also examined.

The majority of patients were from sub-Saharan Africa. Most (82%) were taking cART at baseline and 83% had an undetectable viral load (below 400 copies/ml). Median CD4 cell count was 536 cells/mm3.

Yellow fever vaccination is only recommended for asymptomatic HIV-positive patients with a CD4 cell count above 200 cells/mm3. This is because it is a live-attenuated vaccine and therefore poses significant health risk for patients with very weak immune systems. Despite this recommendation, the investigators identified eleven individuals who were immunised against yellow fever while their CD4 cell count was dangerously low.

Overall, PRNT was reactive in 46% of patients before vaccination. A protective immune response was present one, five and ten years post-vaccination in 95%, 86% and 75% of patients, respectively.

In patients with suppressed viral load at the time of immunisation, the proportion with reactive PRNT remained consistently high: 99% at year one, 99% at year five and 100% at year ten.

An undetectable viral load at the time of vaccination was the single biggest determinant of long-term response to the vaccine.

The authors recommend that patients with HIV should be vaccinated against yellow fever once their viral load is suppressed and that they should receive a booster after ten years if they remain on suppressive cART. However, patients who were vaccinated while their viral load was detectable should either have their immune response to the vaccine measured or receive a booster vaccination, irrespective of the time since first yellow fever vaccination.

Source: aidsmap